ZNTLMEDIUM SIGNALFINANCIAL10-K

ZNTL demonstrated improved operational efficiency with 36% reduction in R&D expenses and corresponding improvements in operating losses, though this came alongside a significant 36% decline in stockholders' equity.

The substantial reduction in R&D spending while maintaining clinical progress suggests more disciplined capital allocation, but the sharp decline in equity and current assets indicates the company is burning through its cash reserves. The improved loss metrics are encouraging, but the asset base deterioration raises questions about funding runway for continued operations.

Comparing 2026-03-26 vs 2025-03-26View on EDGAR →
FINANCIAL ANALYSIS

ZNTL showed mixed financial signals with R&D expenses declining 36% to $107.3M, leading to improved operating losses (-20%) and net losses (-17%), suggesting better cost management. However, the balance sheet contracted significantly with stockholders' equity falling 36% to $216.2M, current assets declining 34% to $253.2M, and total assets dropping 33% to $289.0M, indicating substantial cash burn. While operating cash flow improved 27% to -$125.2M, the overall picture suggests ZNTL is managing expenses more effectively but continues to deplete its capital base at a concerning rate.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
-36%
$167.8M$107.3M

R&D spending cut 36% — could signal cost discipline or concerning reduction in innovation investment.

Stockholders Equity
Balance Sheet
-35.9%
$337.2M$216.2M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-34.4%
$386.1M$253.2M

Current assets declined 34.4% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-32.9%
$430.3M$289.0M

Total assets contracted 32.9% — asset sales, write-downs, or balance sheet optimization underway.

Current Liabilities
Balance Sheet
-30.7%
$52.7M$36.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Operating Cash Flow
Cash Flow
+26.7%
-$170.9M-$125.2M

Operating cash flow grew 26.7% — strong conversion of earnings to cash, healthy business fundamentals.

Total Liabilities
Balance Sheet
-21.9%
$93.2M$72.8M

Liabilities reduced 21.9% — deleveraging improves balance sheet strength and financial flexibility.

Operating Income
P&L
+20.1%
-$191.2M-$152.8M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+17.4%
-$165.8M-$137.1M

Net income grew 17.4% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-26
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 71 Item 7A.
We rely, and expect to continue to rely, on third parties, including independent clinical investigators and contract research organizations, or CROs, to conduct certain aspects of our preclinical studies and clinical trials.
We contract with third parties for the manufacture of azenosertib for preclinical studies and ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization.
This reliance on third parties increases the risk that we will not have sufficient quantities of azenosertib or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
Azenosertib also has broad franchise potential beyond Cyclin E1-positive PROC.
+7 more — sign up free →
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 70 Item 7A.
We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our preclinical studies and clinical trials.
Azenosertib also has broad franchise potential beyond Cyclin E1+ PROC.
In January 2025, we disclosed a significant amount of clinical data showing an objective response rate, or ORR, of over 30% and a manageable safety profile in patients with Cyclin E1+ PROC who received azenosertib at our primary dose-of-interest, 400 mg QD 5:2 (intermittent daily dosing on a five days on, two days off dosing schedule).
We plan to initiate enrollment of our DENALI Part 2 clinical trial of azenosertib in patients with Cyclin E1+ PROC in the first half of 2025 and to disclose topline data from the trial by year end 2026.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →